Hypofractionated 44 Gy in 20 fractions versus conventional chemoradiation in cervical cancer: 2-year results of the randomized HYPOCx-iRex trial with an exploratory pooled analysis of a single-institute EMBRACE-II cohort.
Tissana Prasartseree, Pittaya Dankulchai, Wiwatchai Sittiwong et al.
✦ AI-curated · Sources linked
In 30 seconds
The randomized HYPOCx-iRex trial compared hypofractionated chemoradiation (44 Gy in 20 fractions) with conventional chemoradiation (45 Gy in 25 fractions) for locally advanced cervical cancer; an exploratory pooled analysis added a nonrandomized single-institute cohort. At 2 years, late grade ≥2 gastrointestinal toxicity was numerically higher with hypofractionation (23.8% vs. 10.8%, pLR = 0.168), while locoregional control and overall survival showed favorable but nonsignificant trends. Hypofractionation shortened median overall treatment time (39 vs. 46 days, p < 0.001) and was reported as cost-effective. The authors call for further brachytherapy optimization and validation before clinical adoption.
Key findings
- Median overall treatment time was 39 versus 46 days with hypofractionated versus conventional treatment (p < 0.001).
- Two-year late grade ≥2 GI toxicity was 23.8% versus 10.8% (pLR = 0.168); grade ≥3 toxicity was 19.1% versus 5.3% (pLR = 0.066).
- Locoregional control was 95.2% versus 77.5% (HR = 0.43, pLR = 0.260), and overall survival was 100% versus 76.8% (HR = 0.22, pLR = 0.107); both differences were nonsignificant.
- The 44 Gy/20-fraction regimen was reported as dominant in cost-effectiveness analyses.
Why it matters
The findings highlight a potential trade-off: a shorter treatment course and favorable cost-effectiveness alongside numerically higher late gastrointestinal toxicity. The nonsignificant oncologic outcome trends are encouraging but do not establish superiority. The reported association between brachytherapy conformity and toxicity also points to treatment planning as a possible focus for further evaluation.
What to keep in mind
The randomized comparison was small, and the pooled analysis included a nonrandomized cohort. The authors describe the conformity threshold and cost-effectiveness findings as hypothesis-generating and requiring validation.